We use murine gallbladder derived organoids to demonstrate how activation of mutant Kras or ERBB2 in conjunction with loss-of-function of single or multiple tumor suppressor genes reliably leads to GBC in recipient mice. The gene discussed is KRAS; the disease is neoplasm.